Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891015 | 0.79 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2KDM4ELMNAMAPT | |
| SCHEMBL28432330 | 0.74 | ALDH1A1 (0.51) | ALDH1A1GAALMNAMAPK10MEN1 | |
| SCHEMBL6017355 | 0.74 | TDP1 (0.54) | ALDH1A1KDM4ETDP1PKML3MBTL1 | |
| SCHEMBL30798461 | 0.72 | TDP1 (0.53) | ALDH1A1SMN1; SMN2KDM4ETDP1PKM | |
| SCHEMBL4074618 | 0.72 | TDP1 (0.53) | ALDH1A1SMN1; SMN2KDM4ETDP1PKM | |
| SCHEMBL4556786 | 0.72 | TDP1 (0.53) | ALDH1A1KDM4ETDP1PKML3MBTL1 | |
| SCHEMBL29361610 | 0.72 | TDP1 (0.53) | ALDH1A1KDM4ETDP1PKML3MBTL1 | |
| SCHEMBL16790454 | 0.71 | TDP1 (0.51) | ALDH1A1KDM4ETDP1PKML3MBTL1 | |
| SCHEMBL22912507 | 0.71 | TDP1 (0.51) | ALDH1A1SMN1; SMN2KDM4ETDP1PKM | |
| SCHEMBL29363643 | 0.71 | TDP1 (0.51) | ALDH1A1SMN1; SMN2KDM4ETDP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7465722-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7329653-B2 | Cyclohexylphenyl vasopressin agonists | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1381608-B1 | CYCLOHEXYLPHENYL VASOPRESSIN AGONISTS | WYETH CORP (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7223752-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060276456-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-7109193-B2 | Tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-09-19 | — | — | US | disclosed |
| CN-1273469-C | Tricyclic diazepines as tocolytic oxytocin receptor antagonists | WYETH CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| US-20060183734-A1 | Cyclohexylphenyl vasopressin agonists | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| US-20030018024-A1 | Biphenyl vasopressin agonists | WYETH | 2003-01-23 | — | — | US | disclosed |
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | disclosed |
| US-20020198191-A1 | Medicine for inducing temporary delay of urination or treatment of disorders of diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or bleeding and coagulation disorders | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2002083685-A1 | CYCLOHEXYLPHENYL VASOPRESSIN AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083683-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083145-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083678-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | AVPR2, AVPR1B, SSTR3 | ALDH1A1 1977/4885SMN1; SMN2 2652/4885GAA 4814/4885 |
| US-20060276456-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | ALDH1A1 1977/4885SMN1; SMN2 2652/4885GAA 4814/4885 |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | ALDH1A1 3354/4885SMN1; SMN2 2129/4885GAA 4863/4885 |
| US-20020198191-A1 | Medicine for inducing temporary delay of urination or treatment of disorders of diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or bleeding and coagulation disorders | F2, AVPR2, SHBG | ALDH1A1 1408/4885SMN1; SMN2 2572/4885GAA 2390/4885 |
| US-20060183734-A1 | Cyclohexylphenyl vasopressin agonists | AVPR2, AVPR1A, AVPR1B | ALDH1A1 2998/4885SMN1; SMN2 2442/4885GAA 3799/4885 |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, OPRK1 | ALDH1A1 3035/4885SMN1; SMN2 2035/4885GAA 4840/4885 |
| US-20030018024-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, AVPR1A | ALDH1A1 1159/4885SMN1; SMN2 2184/4885GAA 4806/4885 |
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | ALDH1A1 2795/4885SMN1; SMN2 2389/4885GAA 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.